Verona Pharma plc (NASDAQ:VRNA) is set to announce second quarter earning results on Friday 14th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, VRNA to report 2Q20 loss of $ 0.47 per share.
For the full year, analysts anticipate loss of $ 1.82 per share bottom line.
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of VRNA was $ 7.18, representing a 257.21 % increase from the 52 week low of $ 2.01 and a 54.3 % decrease over the 52 week high of $ 15.71.
The company has a market capital of $ 401.90 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”VRNA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The companys product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
